Proteins and Peptides

07 Sep 2022 Fresenius Kabi Receives U.S. FDA Approval for Biosimilar Stimufend® (pegfilgrastim - fpgk)
01 Sep 2022 Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1/1b Clinical Trial of WTX-124 for the Treatment of Patients with Selected Solid Tumors
01 Sep 2022 Ascendis Pharma Submits TransCon™ PTH New Drug Application to the U.S. FDA for Adult Patients with Hypoparathyroidism
01 Sep 2022 XenpozymeTM (olipudase alfa-rpcp) approved by FDA as first disease-specific treatment for ASMD (non-CNS manifestations)
30 Aug 2022 FDA grants priority review to efanesoctocog alfa for people with hemophilia A
25 Aug 2022 Aktis Oncology raises $84 million to advance novel targeted alpha radiopharmaceuticals
25 Aug 2022 Pieris Pharmaceuticals Announces Presentation of Preclinical Data for Inhaled Jagged-1 Inhibitor PRS-400 at ERS
25 Aug 2022 Apellis Announces 24-Month Results Showing Increased Effects Over Time with Pegcetacoplan in Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA)
23 Aug 2022 Novo Nordisk successfully completes phase 2 trial with CagriSema in people with type 2 diabetes
19 Aug 2022 Innovative Cellular Therapeutics (ICT) Announces First Patient Enrolled for the Company’s Phase I Trial of GCC19CART for Relapsed/Refractory Metastatic Colorectal Cancer
18 Aug 2022 Immedica Pharma AB submits Marketing Authorisation Application to the European Medicines Agency seeking approval of pegzilarginase for the treatment of Arginase 1 Deficiency (ARG1-D)
03 Aug 2022 Sciwind Biosciences Announces Positive Topline Results from 20-week Phase 2 Clinical Trial of XW003 (Ecnoglutide), a novel long-lasting GLP-1 analogue, in Adult Patients with Type 2 Diabetes in China
29 Jul 2022 Novo Nordisk achieves primary objectives of ONWARDS 3 and 4 trials with once-weekly insulin icodec demonstrating superior reduction in HbA1c vs insulin degludec in ONWARDS 3
28 Jul 2022 Medicenna Announces New Clinical Data Providing Preliminary Evidence of MDNA11’s Single Agent Anti-Cancer Activity in the Phase 1/2 ABILITY Study
27 Jul 2022 SOTIO Doses First Patient in AURELIO-04 Phase 2 Trial of SOT101 in Combination with KEYTRUDA® (pembrolizumab)
26 Jul 2022 LFB Announces the Approval of CEVENFACTA® (eptacog beta) in the European Union
19 Jul 2022 Preclinical Data Demonstrate Potential of Creative Bio-Peptides’ Multi-Chemokine Receptor Antagonist RAP-103 to Enhance Opioid Analgesia and Inhibit Opioid-derived Dependence, Withdrawal and Respiratory Depression
19 Jul 2022 Medikine Initiates First Clinical Trial of its Lead Program, an Interleukin-7 Mimetic, Under Management Team with Expertise in Next-Generation Cytokine Drug Discovery and Development
19 Jul 2022 Acadia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Trofinetide for the Treatment of Rett Syndrome
14 Jul 2022 Endevica Bio Doses First Patient in Phase 1 Clinical Trial of TCMCB07 for the Treatment of Cachexia
12 Jul 2022 Coagulant Therapeutics Presents Data for Severe Postpartum Hemorrhage Clinical Candidate, CT-001, at International Society for Thrombosis and Haemostasis Congress
12 Jul 2022 MediWound Announces Positive Initial Data from its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
07 Jul 2022 Biohaven Enrolls First Patient in Phase 3 Trial of Taldefgrobep alfa in Spinal Muscle Atrophy (SMA)
07 Jul 2022 DiaMedica Therapeutics Announces Clinical Hold of its Phase 2/3 ReMEDy2 Clinical Trial for DM199
02 Jul 2022 Pierre Fabre and the EspeRare Foundation administer investigational treatment to first patient in EDELIFE clinical trial for rare genetic disease, XLHED

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top